A Registry for Those at Risk for Pancreatic Cancer
If you’ve lost relatives to pancreatic cancer or have a genetic mutation tied to the disease, joining a tumor registry can help doctors identify early detection and screening options.
New Drug for BRCA Carriers with Advanced Cancer
A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.
Taking Nothing For Granted
After Whipple surgery and chemoradiation for pancreatic cancer, Susan Zbacnik had molecular profiling, genetic testing, and joined vaccine clinical trial.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Immunotherapy Treatments Provide Hope to Pancreatic Cancer Patients
Dr. Robert Vonderheide of the Abramson Cancer Center at the University of Pennsylvania describes immunotherapy trials for pancreatic cancer.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
Can a Pancreatic Cancer Screening Test Become a Reality?
Dr. Felice Schnoll-Sussman discusses screening options for pancreatic cancer, and criteria for people who might want to get screened.
A New Drug Combination to Control Advanced Pancreatic Cancer
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
Exploring the Effectiveness of an Experimental Class of Drug
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
The Impact of BRCA Is Broader Than Breast and Ovarian Cancer
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.
